 GOVX is uniquely positioned with its Phase 2 COVID-19 vaccine candidate for immunocompromised individuals. It has also started a Phase 2 trial as a booster vaccine for the general population. In addition to its GEOCOH04S1 and GEO-CM02 COVID-19 vaccine candidates, it has clinical trials on HIV and early stage candidates for a variety of infectious diseases, funded through non-dilutive sources. 